An update on dual Src/Abl inhibitors

Future Medicinal Chemistry

Volumn 4, Issue 6, 2012, Pages 799-822

  Musumeci, Francesca ^a   Schenone, Silvia ^a   Brullo, Chiara ^a   Botta, Maurizio ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ANTINEOPLASTIC AGENT; AP 24163; AP 24226; AP 24283; BCR ABL PROTEIN; BOSUTINIB; CAPECITABINE; CURCUMIN; DASATINIB; DOXORUBICIN; ERLOTINIB; EXEMESTANE; GEFITINIB; HG 7 85 01; HG 7 8501; HG 7 86 01; IMATINIB; NILOTINIB; PONATINIB; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; SARACATINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 228; ZOLEDRONIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME 22; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; LEUKEMIA; LUNG CANCER; MONOTHERAPY; MYELOID LEUKEMIA; NAUSEA; NEOPLASM; NONHUMAN; OLIGOMERIZATION; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; VOMITING;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIOXOLES; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, MOLECULAR; NITRILES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; QUINAZOLINES; QUINOLINES; SRC-FAMILY KINASES; THIAZOLES;

EID: 84860252260     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.29     Document Type: Review

References (129)

1. Dhut S, Chaplin T, Young BD. Bcr-Abl and Bcr proteins: Biochemical characterization and localization. Leukemia 4, 745-750 (1990).
2. Nagar B, Hantschel O, Young MA et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859-871 (2003).
3. Schenone S, Manetti F, Botta M. Last findings on dual inhibitors of Abl and Src tyrosine-kinases. Mini Rev. Med. Chem. 7, 191-201 (2007).
4. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 19, 5636-5642 (2000).
5. Hu Y, Liu Y, Pelletier S et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet. 36, 453-461 (2004).
6. Klejman A, Schreiner SJ, Nieborowska-Skorska M et al. The Src family kinase Hck couples Bcr/Abl to STAT5 activation in myeloid leukemia cells. EMBO J. 21, 5766-5774 (2002).
7. Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res. 68, 9624-9633 (2008).
8. Schenone S, Bruno O, Radi M, Botta M. New insight into small molecule inhibitors of Bcr-Abl. Med. Res. Rev. 31, 1-41 (2011).
9. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7, 345-356 (2007).
10. Resh MD. Fatty acylation of proteins: New insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim. Biophys. Acta 1451, 1-16 (1999).
11. Waksman G, Shoelson SE, Pant N, Cowburn D, Kuriyan J. Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: Crystal structures of the complexed and peptide-free forms. Cell 72, 779-790 (1993).
12. Musacchio A, Noble M, Pauptit R, Wierenga R, Saraste M. Crystal structure of a Src-homology 3 (SH3) domain. Nature 359, 851-855 (1992).
13. Yu H, Rosen MK, Shin TB, Seidel-Dugan C, Brugge JS, Schreiber SL. Solution structure of the SH3 domain of Src and identification of its ligand-binding site. Science 258, 1665-1668 (1992).
14. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene 23, 7918-7927 (2004).
15. Barouch-Bentov R, Che J, Lee CC et al. A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Mol. Cell 33, 43-52 (2009).
16. Xu W, Doshi A, Lei M et al. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3, 629-38 (1999).
17. Cowan-Jacob SW, Fendrich G, Manley PW et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 13, 861-871 (2005).
18. Zheng XM, Resnick RJ, Shalloway D. A phosphotyrosine displacement mechanism for activation of Src by PTPalpha. EMBO J. 19, 964-978 (2000).
19. Schenone S, Zanoli S, Brullo C, Crespan E, Maga G. Advances in the development of anticancer drugs targeting tyrosine kinases of the Src family. Curr. Drug Ther. 3, 158-176 (2008).
20. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5, 33-44 (2004).
21. Pluk H, Dorey K, Superti-Furga G. Autoinhibition of c-Abl. Cell 108, 247-259 (2002).
22. Barilá D, Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat. Genet. 18, 280-282 (1998).
23. Dorey K, Engen JR, Kretzschmar J et al. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene 20, 8075-8084 (2001).
24. Levinson NM, Kuchment O, Shen K et al. A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol. 4, e144 (2006).
25. Brasher BB, Van Etten RA. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 275, 35631-35637 (2000).
26. Wisniewski D, Lambek CL, Liu C et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 62, 4244-4255 (2002).
27. Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat. Struct. Biol. 9, 117-120 (2002).
28. Van Etten RA. Mechanisms of transformation by the BCR-ABL oncogene: New perspectives in the post-imatinib era. Leuk. Res. 28, S21-S28 (2004).
29. He Y, Wertheim JA, Xu L et al. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 99, 2957-2968 (2002).
30. Majsterek IJ. The rationale engineering of BCR/ABL blockers: An answer to STI571 acquired resistance in leukemia treatment. Leuk. Res. 29, 605-606 (2005).
31. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-Abl-driven K562 cells and is effective against STI571-resistant Bcr-Abl mutants. Clin. Cancer Res. 9, 1267-1273 (2003).
32. Pricl S, Fermeglia M, Ferrone M, Tamborini E. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: Insights from a computational study. Mol. Cancer Ther. 4, 1167-1174 (2005).
33. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358-364 (2006).
34. Zuccotto F, Ardini E, Casale E, Angiolini M. Through the 'gatekeeper door': Exploiting the active kinase. J. Med. Chem. 53, 2681-2694 (2010).
35. Schenone S, Brullo C, Botta M. New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: Tyrosine kinase inhibitors and molecules that act by alternative mechanisms. Curr. Med. Chem. 17, 1220-1245 (2010).
36. Hassan AQ, Sharma SV, Warmuth M. Allosteric inhibition of BCR-ABL. Cell Cycle 9, 3710-3714 (2010).
37. Hanke JH, Gardner JP, Dow RL et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271, 695-701 (1996).
38. Tatton L, Morley GM, Chopra R, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J. Biol. Chem. 278, 4847-4853 (2003).
39. Kong L, Deng Z, Shen H, Zhang Y. Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phosphoro-Src-Y416 and phospho-EGFR-Y1173. Mol. Cell. Biochem. 348, 11-19 (2011).
40. Lombardo LJ, Lee FY, Chen P et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661 (2004).
41. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel Abl inhibitors. Science 305, 399-401 (2004).
42. O'Hare T, Walters DK, Stoffregen EP et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65, 4500-4505 (2005).
43. Hantschel O, Rix U, Schmidt U et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc. Natl Acad. Sci. USA. 104, 13283-13288 (2007).
44. Tokarski JS, Newitt JA, Chang CY et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66, 5790-5797 (2006).
45. Shah NP, Kantarjian HM, Kim DW et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204-3212 (2008).
46. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin. Hematol. 25, 49-61 (1988).
47. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362, 2260-2270 (2010).
48. Cortes JE, Jones D, O'Brien S et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 28, 398-404 (2009).
49. Apperley JF, Cortes JE, Kim D et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: The start a trial. J. Clin. Oncol. 27, 3472-3479 (2009).
50. Li J, Xu G, Yu S, He L, Guo L. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia. J. Int. Med. Res. 39, 337-347 (2011).
51. Ottmann O, Dombret H, Martinelli G et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a Phase 2 study. Blood 110, 2309-2315 (2007).
52. Lilly MB, Ottmann OG, Shah NP et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am. J. Hematol. 85, 164-170 (2010).
53. Aplenc R, Blaney SM, Strauss LC et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: A report from the children's oncology group phase I consortium. J. Clin. Oncol. 29, 839-844 (2011).
54. Porkka K, Koskenvesa P, Lundán T et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112, 1005-1012 (2008).
55. Finn RS, Bengala C, Ibrahim N et al. Phase II trial of dasatinib in triple-negative breast cancer: Results of study CA180059. Cancer Res. 69 (2 Suppl.), (Abstract 3118) (2009).
56. Pichot CS, Hartig SM, Xia L et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br. J. Cancer 101, 38-47 (2009).
57. Yu EY, Massard C, Gross ME et al. Once-daily dasatinib: Expansion of Phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 77, 1166-1171 (2011).
58. Johnson FM, Bekele BN, Feng L et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 4609-4615 (2010).
59. Miller AA, Pang H, Hodgson L et al. A Phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (CALGB 30602). J. Thorac. Oncol. 5, 380-384 (2010).
60. Haura EB, Tanvetyanon T, Chiappori A et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 1387-1394 (2010).
61. Nautiyal J, Banerjee S, Kanwar SS et al. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int. J. Cancer 128, 951-961 (2011).
62. Morton JP, Karim SA, Graham K et al. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 139, 292-303 (2010).
63. Boschelli DH, Ye F, Wang YD et al. Optimization of 4-phenylamino-3- quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem. 44, 3965-3977 (2001).
64. Thaimattam R, Daga PR, Banerjee R, Iqbal J. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Bioorg. Med. Chem. 13, 4704-4712 (2005).
65. Golas JM, Arndt K, Etienne C et al. SKI-606, a 4-Anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63, 375-381 (2003).
66. Puttini M, Coluccia AM, Boschelli F et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib resistant Bcr-Abl+ neoplastic cells. Cancer Res. 66, 11314-11322 (2006).
67. Gambacorti-Passerini C, Kim DW, Kantarjian HM et al. An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 116, (Abstract 208) (2010).
68. Messersmith WA, Krishnamurthi S, Hewes BA et al. Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings 25(18S), 3552 (2007).
69. Campone M, Bondarenko I, Brincat S et al. Phase II study of single-Agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann. Oncol. 23(3), 610-617 (2011).
70. Hebbard L, Cecena G, Golas J et al. Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene 30, 301-312 (2011).
71. Rabbani SA, Valentino ML, Arakelian A, Ali S, Boschelli F. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol. Cancer Ther. 9, 1147-1157 (2010).
72. Rothschild SI, Gautschi O, Haura EB, Johnson FM. Src inhibitors in lung cancer: Current status and future directions. Clin. Lung Cancer 11, 238-242 (2010).
73. Yasmeen A, Alachkar A, Dekhil H, Gambacorti-Passerini C, Al Moustafa AE. Locking Src/Abl tyrosine kinase activities regulate cell differentiation and invasion of human cervical cancer cells expressing E6/E7 oncoproteins of high-risk HPV. J. Oncol. doi:0.1155/2010/530130 (2010) (Epub).
74. Boschelli DH, Wang D, Wang Y et al. Optimization of 7-Alkene-3- quinolinecarbonitriles as Src kinase inhibitors. Bioorg. Med. Chem. Lett. 20, 2924-2927, (2010).
75. Green TP, Fennell M, Whittaker R et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol. Oncol. 3, 248-261 (2009).
76. Hennequin LF, Allen J, Breed J et al. N-(5-chloro-1,3-benzodioxol-4-yl)- 7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin- 4-Amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 49, 6465-6488 (2006).
77. Gwanmesia PM, Romanski A, Schwarz K, Bacic B, Ruthardt M, Ottmann OG. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines. BMC Cancer 9, 53 (2009).
78. Hiscox S, Jordan NJ, Smith C et al. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res. Treat. 115, 57-67 (2009).
79. Chen Y, Alvarez EA, Azzam D et al. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Res. Treat. 128, 69-78 (2011).
80. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene, 27, 6365-6375 (2008).
81. Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int. 103, 434-440 (2009).
82. Purnell PR, Mack PC, Tepper CG et al. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J. Thorac. Oncol. 4, 448-454 (2009).
83. Hannon RA, Clack G, Rimmer M et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-Ascending-dose phase I trial. J. Bone Miner. Res. 25, 463-471 (2010).
84. Tabernero J, Cervantes A, Hoekman K et al. I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings 25(18S), 3520 (2007).
85. de Vries TJ, Mullender MG, van Duin MA et al. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol. Cancer Res. 7, 476-488 (2009).
86. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-focal adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 94, 2199-2203 (2009).
87. Rajeshkumar NV, Tan AC, De Oliveira E et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin. Cancer Res. 15, 4138-4146 (2009).
88. Fury MG, Baxi S, Shen R et al. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res. 31, 249-253 (2011).
89. Nagar B, Bornmann WG, Pellicena P et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236-4243 (2002).
90. Antczak C, Veach DR, Ramirez CN et al. Structure-Activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: Toward selective Abl inhibitors. Bioorg. Med. Chem. Lett. 19, 6872-6876 (2009).
91. O'Hare T, Pollock R, Stoffregen EP et al. Inhibition of wild-Type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: Implications for CML. Blood 104, 2532-2539 (2004).
92. Azam M, Nardi V, Shakespeare WC, Metcalf CA III et al. Activity of dual Src-Abl inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc. Natl Acad. Sci. USA. 103, 9244-9249 (2006).
93. Wang Y, Shakespeare WC, Huang WS et al. Novel N9-Arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 18, 4907-4912 (2008).
94. Zhou T, Commodore L, Huang WS et al. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template. Chem. Biol. Drug Des. 75, 18-28 (2010).
95. Huang WS, Zhu X, Wang Y et al. 9-(arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: Design, synthesis, and biological evaluation. J. Med. Chem. 52, 4743-4756 (2009).
96. Azam M, Powers JT, Einhorn W et al. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chem. Biol. Drug. Des. 75, 223-227 (2010).
97. O'Hare T, Shakespeare WC, Zhu X et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401-412 (2009).
98. Huang WS, Metcalf CA, Sundaramoorthi R et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1- yl)methyl]-3 (trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J. Med. Chem. 53, 4701-4719 (2010).
99. Zhou T, Commodore L, Huang WS et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): Lessons for overcoming kinase inhibitor resistance. Chem. Biol. Drug Des. 77, 1-11 (2011).
100. Schenone S, Brullo C, Botta M. Small molecules ATP-competitive inhibitors of FLT3: A chemical overview. Curr. Med. Chem. 15, 3113-3132 (2008).
101. Gozgit JM, Wong MJ, Wardwell S et al. Potent activity of Ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol. Cancer Ther. 10, 1028-1035 (2011).
102. Hamilton A, Helgason GV, Schemionek M et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119(6), 1501-1510 (2011).
103. Corbin AS, Agarwal A, Loriaux M et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396-409 (2011).
104. Thomas M, Huang WS, Wen D et al. Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg. Med. Chem. Lett. 21, 3743-3748 (2011).
105. Weisberg E, Choi HG, Ray A et al. Discovery of a small-molecule type II inhibitor of wild-Type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: Novel type II inhibitor of gatekeeper mutants. Blood 115, 4206-4216 (2010).
106. Weisberg E, Deng X, Choi HG et al. Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia 24, 1375-1378 (2010).
107. Weisberg E, Choi HG, Barrett R et al. Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol. Cancer Ther. 9, 2468-2477 (2010).
108. Seeliger MA, Ranjitkar P, Kasap C et al. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 69, 2384-2392 (2009).
109. Ranjitkar P, Brock AM, Maly DJ. Affinity reagents that target a specific inactive form of protein kinases. Chem. Biol. 17, 195-206 (2010).
110. Liu H, Li H, Feng Z et al. Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro. Leuk. Lymphoma 50, 437-446 (2009).
111. Yuan X, Zhang Y, Zhang H et al. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo. Leuk. Res. 35, 237-242 (2011).
112. Zhang W. Inhibition of the drug-resistant T315I mutant of Bcr-Abl. Eur. J. Cancer (Suppl. 4), 54 (2006).
113. Shah NP, Kasap C, Paquette R et al. Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228. Blood (ASH Annual Meeting Abstracts) 110, (2007) (Abstract 474).
114. Hill ZB, Perera GK, Maly DJ. A Chemical genetic method for generating bivalent inhibitors of protein kinases. J. Am. Chem. Soc. 131, 6686-6688 (2009).
115. Keppler A, Kindermann M, Gendreizig S, Pick H, Vogel H, Johnsson K. Labeling of fusion proteins of O6-Alkylguanine-DNA alkyltransferase with small molecules in vivo and in vitro. Methods 32, 437-444 (2004).
116. Hill ZB, Perera GK, Maly DJ. Bivalent inhibitors of the tyrosine kinases ABL and SRC: Determinants of potency and selectivity. Mol. Biosyst. 7, 447-456 (2011).
117. Carraro F, Naldini A, Pucci A et al. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J. Med. Chem. 49, 1549-1461 (2006).
118. Manetti F, Brullo C, Magnani M et al. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J. Med. Chem. 51, 1252-1259 (2008).
119. Manetti F, Santucci A, Locatelli GA, Maga G et al. Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice. J. Med. Chem. 50, 5579-5588 (2007).
120. Schenone S, Brullo C, Musumeci F, Botta M. Novel dual Src/Abl inhibitors for hematologic and solid malignancies. Expert Opin. Investig. Drugs 19, 931-945 (2010).
121. Falchi F, Manetti F, Carraro F et al. 3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors. ChemMedChem 4, 976-987 (2009).
122. Manetti F, Locatelli GA, Maga G et al. A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J. Med. Chem. 49, 3278-3286 (2006).
123. Santucci MA, Corradi V, Mancini M et al. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines. ChemMedChem 4, 118-126 (2009).
124. 34+ cells. Invest. New Drugs 28, 876-878 (2010).
125. Radi M, Dreassi E, Brullo C et al. Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: A lead optimization study. J. Med. Chem. 54, 2610-2626 (2011).
126. Rossi A, Schenone S, Angelucci A et al. New pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. FASEB J. 24, 2881-2892 (2010).
127. Radi M, Brullo C, Crespan E et al. Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells. Bioorg. Med. Chem. Lett. 21, 5928-5933 (2011).
128. Baghdadi TA, Abonour R, Boswell HS. Novel combination treatments targeting chronic myeloid leukemia stem cells. Clin. Lymphoma Myeloma Leuk. 12(2), 94-105 (2011).
129. Woessner DW, Lim CS, Deininger MW. Development of an effective therapy for chronic myelogenous leukemia. Cancer J. 17, 477-486 (2011)